In 2004, chip makers Intel and Infineon's corporate venturing fund participated in BridgeCo's $16m series C financing round, with Intel Capital having previously invested in its B round.

Clearwell has raised $33m from Northgate Capital, which is majority funded by India-based industrial conglomerate Religare Enterprises, and venture capital firms DAG Ventures (formerly known as Duff Ackerman & Goodrich), Redpoint Ventures and Sequoia Capital.

PrimeTel examines exit options.

The $750m purchase price for Advanced BioHealing gives a 13 times return for Safeguard, which invested $26m.

News provider International Financing Review (IFR) said the Beijing-based company could soon mandate banks on the initial public offering, which is planned for the final three months of the year.

Monsanto had bought 3.3 million shares in Ceres's E round last year at $6.50 per share following a $137m collaboration signed in 2002 applying genomics technologies to identify genes that provide improvements in corn, soybean and certain other row crops, according to its regulatory filing.

In March, Solazyme aimed to raise $100m but now said it would issue 11.5 million shares, including 1.5 million if demand is strong enough as a so-called greenshoe allotment, at between $15 and $17 each. At the top end of its pricing range, Solazyme would have an initial market capitalisation of $965m.

Fusion-io will issue 10.76 million shares with its owners selling 1.5 million at up to $15 each, before 1.85 million shares can be sold if demand is strong enough.